CSF3 and non-Hodgkin lymphoma: G-CSF to facilitate dose dense chemotherapy (two vs three weekly CHOP) in the first-line therapy of aggressive NHL (Pfreundschuh et al, 2004a, 2004b) improved 5-year event-free and overall survivals without any significant increase in the incidence of second cancers in the dose dense treatment arms after 58 months median follow-up.